(Reuters) – AbbVie Inc on Thursday raised its 2023 profit forecast on a less-than-feared hit to U.S. sales of arthritis drug Humira from rival biosimilar drugs.
The company now expects 2023 adjusted earnings to be between $10.72 and $11.12 per share, from between $10.62 and $11.02 it provided earlier this month.
Analysts on average have estimated annual adjusted profit of $10.94 per share, according to Refinitiv IBES data.
(Reporting by Mariam E Sunny and Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)